Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
Laura FiondaElena RossiniAntonio LaulettaLuca LeonardiLaura TufanoRocco CostanzoPaolo MarchettiMarco SalvettiMatteo GaribaldiStefania MorinoGiovanni AntoniniPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)
Eculizumab potentially offers a mechanism-based treatment of MG in patients under anti-programmed cell death protein 1 (PD-1) agents, without interfering with their mechanism of action and avoiding their discontinuation. Larger case series deserve to be evaluated.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic obstructive pulmonary disease
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- intensive care unit
- patient reported outcomes
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- mechanical ventilation
- respiratory failure